These activities are supported by an educational grant from Bayer HealthCare Pharmaceuticals.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for prostate cancer. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist video case presentations
• Interactive audience polling and extensive Q&A

MODULE 1: Hormonal Treatment for Nonmetastatic Prostate Cancer

MODULE 2: Optimal Use of Secondary Hormonal Therapy for Metastatic Hormone-Sensitive Prostate Cancer

MODULE 3: Current and Future Applications of Hormonal Therapy in the Treatment of Metastatic Castration-Resistant Prostate Cancer

MODULE 4: Side Effects Associated with Hormonal Therapy for Prostate Cancer

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives

• Infer how various clinical and biologic factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for patients considering the potential benefits and risks of commonly used forms of androgen deprivation therapy.
• Assess clinical research findings with secondary hormonal therapy for nonmetastatic castration-resistant prostate cancer (CRPC), and appreciate how available agents can be integrated into current clinical algorithms.
• Explore available data with secondary hormonal therapy for hormone-sensitive metastatic prostate cancer, and use this information to counsel patients regarding therapeutic options.
• Evaluate available and emerging data sets demonstrating the efficacy and safety of secondary hormonal therapy in combination with other systemic therapies (eg, chemotherapy, PARP inhibitors) for prostate cancer, and consider the applicability of these findings to current and future disease management.
• Apply clinical research findings in the best-practice selection and sequencing of hormonal therapy and other available systemic treatments for patients with metastatic CRPC.
• Understand the potential side effects associated with hormonal agents commonly employed in the management of prostate cancer, and develop strategies to prevent, mitigate and manage toxicities.
• Recall research investigating novel applications of hormonal therapy, and counsel selected patients with localized or metastatic prostate cancer regarding participation in clinical trials.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Prof Oudard has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Prof Fizazi — Advisory Board (Honoriaria to Me): CureVac, Orion Corporation; Advisory Board or Speaking Engagements (Honoraria Provided to My Institution): Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Sanofi. Dr Smith — Advisory Committee, Consulting Agreements and Contracted Research: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by an educational grant from Bayer HealthCare Pharmaceuticals.